On September 5, 2023, the United States Government Accountability Office (GAO) published its report titled Medicare Part D: CMS Should Monitor Effects of Rebates on Plan Formularies and Beneficiary Spending.The report...more
10/5/2023
/ Beneficiaries ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
GAO ,
Generic Drugs ,
Manufacturers ,
Medicare ,
Medicare Part D ,
Negotiations ,
Pharmaceutical Industry ,
Rebates ,
Sponsors